Delta Life Science

The demand for faster development of more effective drugs and diagnostics tests is increasing.  At the same time, development is also becoming more complex, since vastly more antibodies need to be examined. Label-free biosensing enables researchers to study interactions between molecules, conduct kinetics screening for drug candidates, select high-quality antibodies based on kinetics and develop rapid, qualitative biomarker assays in real time. But current solutions require large amounts of precious samples, and are prohibitively expensive and painfully slow. More affordable solutions are less sensitive and provide less accurate results.

Delta Life Science is dedicated to accelerating life science research. They have developed inQuiQ^TM – the first commercially available, compact, high-speed solution that is affordable, highly accurate and reliable. inQuiQ is now available to academic and pharma researchers, so as to further validate the technology in real-world lab settings.

inQuiQ is driven by Nanophotonic Evanescent Field Sensing technology based on photonic chips that carry optical circuits instead of electronics. This highly sensitive technology enables academic and pharma researchers to get better results in a fraction of the time, thereby accelerating drug- and diagnostic test development. inQuiQ offers:

• More data from each sample: up to 16 analytes per run
• Data in minutes, not hours: high-speed results to accelerate research
• Up to 120 analyses per day: far more than current methods
• From 10,000 to 10 antibodies: faster, more accurate identification of relevant antibodies
• Wider range of sample volumes: from 25µL to 2ml
• Faster assay development: up to four times faster than traditional methods
• Affordability: a fraction of the cost of current market standards
• High accuracy: even in complex matrices

The combination of these unique features goes far beyond providing a strong return on investment. Results will be more accurate than those found in traditional testing methods. Researchers will save significant amounts of time and money uncovering effective candidates. Moreover, they will achieve faster time to market for their drug compounds.

Delta Life Science believes that the more academic and pharma researchers who can reliably and affordably use the technology, the faster development will go for the entire value chain. That’s why they made inQuiQ as compact as a high-end coffee machine, easy to use and affordable for all. The technology has been proven to work in laboratory settings, and Delta Life Science is now offering inQUiQ instruments to researchers eager to validate their efficacy in the real world. At the same time, Delta Life Science is already developing the next generation of biosensor technology, capable of analysing up to 768 samples per day.